No results for ‘’
NGL Fine Chem Ltd
₹2811.80
(0.32%)
Thu, 18 Jun 2026, 03:58 pm
Health Technology
Pharmaceuticals: Major
24.5KNGL Fine Chem Return on Equity (ROE) History
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 2.21 | 4.34 | 3.43 | 7.08 | 3.25 | 3.37 | 5.35 | 12.26 | 15.93 | 20.15 | 14.42 | 18.78 | 16.70 | 24.24 | 36.08 | 31.25 | 32.59 |
| Price to book ratio | 0.40 | 0.86 | 0.52 | 0.43 | 0.47 | 0.62 | 1.36 | 3.16 | 3.99 | 3.52 | 3.15 | 1.58 | 6.13 | 5.95 | 3.32 | 4.92 | 2.44 |
| Price to sales ratio | 0.18 | 0.42 | 0.24 | 0.21 | 0.17 | 0.19 | 0.52 | 1.47 | 2.47 | 2.29 | 1.92 | 1.05 | 3.67 | 3.81 | 2.66 | 3.81 | 1.87 |
| Price to cash flow ratio | 0 | 7.98 | 2.06 | 4.85 | 171.79 | 95.14 | 4.80 | 14.54 | 25.20 | 12.07 | 43.07 | 8.48 | 36.83 | 94.45 | 21.15 | 63.96 | 20.06 |
| Enterprise value | 7.38Cr | 15.75Cr | 13.78Cr | 16.84Cr | 21.25Cr | 30.8Cr | 53.83Cr | 149Cr | 252Cr | 270Cr | 306Cr | 171Cr | 930Cr | 1210Cr | 719Cr | 1270Cr | 700Cr |
| Enterprise value to EBITDA ratio | 1.78 | 3.13 | 2.84 | 4.98 | 3.05 | 2.86 | 4.15 | 6.78 | 11.57 | 14.34 | 9.22 | 8.87 | 10.98 | 17.74 | 20.58 | 23.63 | 20.07 |
| Debt to equity ratio | 0.38 | 0.37 | 0.39 | 0.60 | 0.67 | 0.68 | 0.40 | 0.33 | 0.38 | 0.37 | 0.29 | 0.29 | 0.11 | 0.15 | 0.15 | 0.13 | 0.27 |
| Return on equity % | 0 | 22 | 16.26 | 6.31 | 15.67 | 20.33 | 29.04 | 29.59 | 28.73 | 19.29 | 24.52 | 8.72 | 44.76 | 27.90 | 9.63 | 17.03 | 7.75 |
NGL Fine Chem Ltd Return on Equity
The NGL Fine Chem Ltd Return on Equity is a key financial metric used by investors to evaluate NGL Fine Chem Ltd's valuation, profitability, and overall financial performance. Tracking the NGL Fine Chem Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
NGL Fine Chem Ltd (NSE: NGLFINE, BSE: 524774) is currently trading at ₹2811.80, with a market capitalization of ₹1739.73Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the NGL Fine Chem Ltd Return on Equity is essential for fundamental analysis.
NGL Fine Chem Ltd Return on Equity Current Value
The current NGL Fine Chem Ltd Return on Equity stands at 7.75.
The NGL Fine Chem Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
NGL Fine Chem Ltd Return on Equity Historical Trend
The NGL Fine Chem Ltd Return on Equity has shown the following historical trend:
- 2024: 7.75
- 2023: 17.03
- 2022: 9.63
- 2021: 27.90
- 2020: 44.76
The decline in NGL Fine Chem Ltd Return on Equity indicates improving financial efficiency or better earnings growth.
What NGL Fine Chem Ltd Return on Equity Indicates for Investors
The NGL Fine Chem Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
NGL Fine Chem Ltd Return on Equity Analysis Summary
The NGL Fine Chem Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking NGL Fine Chem Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of NGL Fine Chem Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.